 WATERTOWN, Mass.--BUSINESS WIRE--Kala Pharmaceuticals, Inc. NASDAQ:KALA, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. We are early in the launch of EYSUVIS and encouraged by our progress to establish the product as the first and only prescription therapy specifically for the short-term treatm 